These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 520727

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [The use of an injectable anti-aldosteron agent in the treatment of secondary hyperaldosteronism].
    Tartagni F, Ambrosioni E.
    Boll Soc Ital Cardiol; 1976; 21(4):725-7. PubMed ID: 1031037
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
    Coltorti M, Radaeli E, Ciaccio S, Corsini R, Trebbi R.
    Clin Ter; 1976 Feb 15; 76(3):215-34. PubMed ID: 963962
    [No Abstract] [Full Text] [Related]

  • 6. [Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
    Gorbach HC, Bräuninger HJ.
    MMW Munch Med Wochenschr; 1975 Sep 15; 117(37):1483-6. PubMed ID: 810673
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Potassium canreonate in neurosurgical brain edema].
    Mille T, Rodriguez R, Baena Y.
    Minerva Chir; 1975 Sep 15; 30(13-14):781-9. PubMed ID: 1221307
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of digitalis toxicity with intravenous potassium canrenoate.
    Gavrilescu G, Cristodorescu R, Deutsch G, Berger E.
    Agressologie; 1977 Sep 15; 18(3):167-71. PubMed ID: 920909
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Indication and experience with an intravenously administered aldosterone-antagonist (soldactone) (author's transl)].
    Kirsch R.
    Schweiz Rundsch Med Prax; 1975 Nov 04; 64(44):1414-7. PubMed ID: 1236699
    [No Abstract] [Full Text] [Related]

  • 17. [Brain edema in neurosurgery. Trial with an aldosterone-antagonist (soldactone) (author's transl)].
    Anderes JP, de Tribolet N, Zander E.
    Schweiz Rundsch Med Prax; 1977 Aug 09; 66(32):1020-6. PubMed ID: 556440
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension].
    Consolo F, Ferraù O, Pitrone F, Luzza G, Russo A, Virga T.
    Boll Soc Ital Biol Sper; 1975 Dec 30; 51(24):1943-9. PubMed ID: 1231877
    [No Abstract] [Full Text] [Related]

  • 20. [Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
    Costa FV, Borghi C, Mussi A, Ambrosioni E.
    Minerva Cardioangiol; 1988 Oct 30; 36(10):503-7. PubMed ID: 3226562
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.